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ABSTRACT
◥
YAP and TAZ are central determinants of malignancy; how-
ever, their functions remain still undruggable. We identified
TGFb-activated kinase 1 (TAK1) as a central hub integrating
the most relevant signals sustaining pancreatic cancer aggres-
siveness and chemoresistance. Glycogen synthase kinase (GSK)3
is known to stabilize TAK1, and its inhibition causes a reduction
in TAK1 levels. Here, we hypothesized that TAK1 could sustain
YAP/TAZ program, and thus, modulation of TAK1 expression
through the inhibition of GSK3 could impair YAP/TAZ func-
tions in pancreatic cancer.
Differentially expressed transcripts between pancreatic cancer
cells expressing scramble or TAK1-specific shRNA were annotat-
ed for functional interrelatedness by ingenuity pathway analysis.
TAK1 expression was modulated by using different GSK3 inhi-
bitors, including LY2090314. In vivo activity of LY2090314 alone
or in combination with nab-paclitaxel was evaluated in an ortho-
topic nude mouse model.
Differential gene expression profiling revealed significant
association of TAK1 expression with HIPPO and ubiquitina-
tion pathways. We measured a significant downregulation
of YAP/TAZ and their regulated genes in shTAK1 cells.
TAK1 prevented YAP/TAZ proteasomal degradation in a
kinase independent manner, through a complex with TRAF6,
thereby fostering their K63-ubiquitination versus K48-
ubiquitination. Pharmacologic modulation of TAK1 by using
GSK3 inhibitors significantly decreased YAP/TAZ levels and
suppressed their target genes and oncogenic functions.
In vivo, LY2090314 plus nab-paclitaxel significantly pro-
longed mice survival duration.
Our study demonstrates a unique role for TAK1 in con-
trolling YAP/TAZ in pancreatic cancer. LY2090314 is a novel
agent that warrants further clinical development in combi-
nation with nab-paclitaxel for the treatment of pancreatic
cancer.
Introduction
Pancreatic cancer is among the most lethal and inadequately
understood human malignancies (1, 2), and will seemingly become
the second leading cause of cancer-related death by 2030 in Western
countries. Pancreatic cancer patients’ prognosis is a dismal, mainly
because of the early metastatic behavior of the disease, its aggres-
siveness, and it is the unique resistance to standard of care chemo-
therapeutic agents (3).
The transcriptional regulators Yes Associated Protein (YAP) and
transcriptional coactivator with a PDZ-binding domain (TAZ) are
emerging as central determinants of malignancy, due to their major
role in sustaining initiation, progression, metastasis, and chemoresis-
tance of tumors, and inducing cancer stem cells phenotype. In
pancreatic cancer, YAP represents a critical oncogenic effector of
KRAS-initiated tumor progression (4). The survival of KRAS addicted
tumor cells was recently associated to YAP1 activation (5). Moreover,
YAP activation was necessary to sustain KRAS-independent sponta-
neous recurrence of pancreatic cancer developed in KRASG12D inacti-
vatedmice (6). However, the activity of these transcriptional regulators
remains still undruggable to date, and just the dissection of the
different signaling pathways that sustain their activation could facil-
itate the development of new therapeutic approaches (7). Although the
Hippo pathway is acknowledged as the main regulator of YAP/TAZ,
recent studies have identified novel upstream signaling pathways
widening the complexity of their regulation (8).
TAK1 is a serine/threonine kinase constituting the cellular hub for
several cytokine-mediated signaling, which critically regulates inflam-
matory responses and cell survival (9, 10) by controlling the activation
of transcription factors such as AP-1 and NF-kB (11, 12). We
demonstrated that targeting the kinase activity of TAK1 dramatically
led to a proapoptotic phenotype and, in turn, to a significantly higher
sensitivity to chemotherapy and radiotherapy in pancreatic (13) and
esophageal carcinoma (14). Despite the variety of compounds target-
ing TAK1 kinase activity, none of them has progressed into clinical
development to date.
Glycogen synthase kinase (GSK)3 is a multifunctional serine/thre-
onine kinase that is encoded by 2 closely related genes, GSK-3a and
GSK-3b. GSK3 has been implicated in a number of human malig-
nancies, including pancreatic cancer. In particular, a recent study
demonstrated that GSK-3a interacts with TAK1 thus stabilizing the
TAK1–TAB complex. This promotes noncanonical NF-kB signaling
in pancreatic cancer cells. Pharmacologic inhibition of GSK-3 caused a
significant reduction of TAK1 levels (15).
In this study, we explored novel downstream signaling of TAK1,
and hypothesized that this kinase could sustain the essential role of
YAP/TAZ program in pancreatic cancer. Thus, targeting TAK1
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expression by inhibiting GSK3 could suppress YAP/TAZ expression
and modulate, in turn, their contribution to the malignancy and
treatment resistance of this disease.
Materials and Methods
Cell cultures and reagents
Human pancreatic cancer cell lines AsPC1, Panc1 were purchased
from the ATCC. MDA-Panc28 cell line was a kind gift by Dr. Paul J.
Chiao. Panc1, AsPC1, and MDA-Panc28 pancreatic cancer cell lines
silenced for the expression of TAK1 were established as described by
Melisi and colleagues (13). All cell lines used in this studywere cultured
as monolayers at 37C, 5% CO2 in high glucose DMEM (Catalog No.
41966-029; Life Technologies), supplemented with 10% heat-
inactivated FBS (Catalog No. 10270-106; Life Technologies),
2 mmol/L L-glutamine (Catalog No. BE17-605E; Lonza), 100 IU/mL
penicillin and 100 mg/mL streptomycin (Catalog No. 15140-122; Life
Technologies), and kept in culture formaximum1month. All cell lines
used in this study were authenticated using DNA fingerprinting at the
genomic core facility at Wayne State University (2009) and routinely
tested for mycoplasma presence using the MycoAlert Mycoplasma
Detection Kit (Catalog No. LT07-118; Lonza).
(5Z)-7-oxozeaenol TAK1 kinase selective inhibitor (TOCRIS Bio-
science) was dissolved in 100% DMSO at a stock concentration of
10 mmol/L (16). Lithium chloride (Catalog No. L4408), a nonspecific
oralGSK3 inhibitor (IC50¼ 10mmol/L)was purchased byAppliChem
and was dissolved in sterile water at a stock concentration of
5 mmol/L. A working concentration of 20 mmol/L has been used in
all the in vitro assays. LY2090314 (Catalog No. S7063) and CHIR-
99021 (Catalog No. S1263) were purchased from Selleckchem and
dissolved inDMSO.Gemcitabine (Accord), oxalipatin (Accord), SN38
(Campto, ref. 17), and nab-paclitaxel (Celgene) were used at the
indicated concentrations for the indicated time. The proteasome
inhibitor MG132 (Z-Leu-Leu-Leu-al, C2211; Sigma-Aldrich) was
dissolved in 100% DMSO and used at a 5 mmol/L concentration for
24 hours. For in vivo experiments, LY2090414 was dissolved in 5%
Tween-80 (A4743; Applichem) in saline. Drug interactions were
studied for synergistic effect according to Chou and Talalay method
by CalcuSyn software, as well as to Bliss independence using Chalice
Analyzer online (18). Chemical structures for MG-132, LY2090314,
and CHIR-99021 are shown in Supplementary Fig. S1A.
Gene expression microarrays and pathway analysis
Total RNA was extracted using TRizol reagent (Catalog No. 15596-
018; Life Technologies) following manufacturer's instruction. RNA
quality was assessed by agarose gel electrophoresis. Total RNA was
quantified by reading the absorbance at 260 nm using a Nanodrop
(Thermo Fisher Scientific). Differences in gene expression between
control and silenced TAK1 cells were examined using IlluminaHuman
48k gene chips (D-103-0204; Illumina) as previously described in
ref. 19. Briefly, 500 ng total RNA were reverse-transcribed and cRNA
was synthesized and biotinylated using the IlluminaTotalPrep RNA
Amplification Kit (AMIL1791; Ambion). cRNAs (750 ng) were
hybridized using Illumina Human 48k gene chips (Human HT-12
V4 BeadChip). Array were washed with Illumina High Temp Wash
Buffer for 10 minutes at 55C, and stained with streptavidin-Cy3 dyes
(Amersham Biosciences). The Illumina Genome Studio software
(Genome Studio V2011.1) was used to obtain probe intensity. Raw
data were Loess normalized with the Lumi R package and further
processed with Excel software. Each microarray experiment was
repeated twice. Network and functional interrelatedness were studied
for the differentially expressed genes using the Ingenuity Pathway
Analyses (IPA) software program (Ingenuity Systems).
Cell transduction
The expression vector for either murine wild-type TAK1 or murine
kinase-dead K63W TAK1 (20) and packaging vectors were cotrans-
fected into 293T cells. Seventy-two hours posttransfection, super-
natants containing virus were filtered through a 0.45 mm filter (Corn-
ing, Inc.). AsPc-1, PANC-1, and MDAPanc-28 cells were transduced
by the lentivirus in the presence of the polycation polybrene and lysed
72 hours post infection to obtain cellular extracts.
Reverse transcription and qRT-PCR
Differences in gene expression were measured as described previ-
ously (21). Total RNA was extracted using TRizol reagent and
quantified by Nanodrop. One microgram o RNA was reverse-
transcribed with High Capacity cDNA Reverse Transcription Kit
(Catalog No. 4368814; Applied Biosystems) following manufacturer's
instruction. cDNA was diluted 1:10 and subjected to RT-PCR using
FAST PowerUp SYBR greenmastermix (CatalogNo. A25742; Applied
Biosystems;). Primerswere purchased by Life Technologies andused at
0.2 mmol/L final concentration. Changes in gene expression were
normalized to b-actin and quantified using the 2DDCT method.
Protein extraction and Western blotting
Western blot analyses were performed as described in ref. 22. Total
protein extracts were prepared by lysing cells in radioimmunopreci-
pitation assay buffer [50 mmol/L Tris HCl (pH 8), 150 mmol/L NaCl,
1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium
dodecyl sulfate]. All protein extracts were quantified by BCA Protein
Assay Kit (23225; Thermo Fisher Scientific) and equal amounts (20–
50 mg of protein extract) were loaded onto SDS-PAGE (4%–20%) and
transferred to polyvinylidene fluoride membranes (Immobilon-P,
Catalog No. IPVH00010; Millipore). Immunoblots were performed
using the indicated antibodies. Antibodies to TAK1 (ab109526,
1:1,000), ITCH (ab109018, 1:1,000), TRAF6 (ab94720, 1:1,000), Ub-
K63 (ab179434, 1:1,000) were all purchased from Abcam. YAP/TAZ
(sc-101199, 1:1,000), CTGF (sc-14939, 1:1,000), GAPDH (sc-166545,
1:50,000) were purchased from Santa Cruz Biotechnology. Secondary
anti-mouse and anti-rabbit antibodies were purchased from Santa
Cruz Biotechnology. All antibodies were diluted in 3% nonfat drymilk
dissolved in Tris-buffered saline (TBS) or 5% BSA/TBS/0.1% Tween-
20. Immunoreactive proteins were visualized with Immobilion West-
ern Kit (Catalog No. WBKLS0500; EMD Millipore) according to the
manufacturer's instructions. Images were acquired using ImageQuant
LAS 4000 mini (GE Healthcare Life Sciences).
Transwell migration assays
Differences in cancer cells migration were measured as described
previously (23). Briefly, 5  104 cells were allowed to migrate for
20 hours. Following removal of nonmigrating cells, cells migrated to
the bottom layer of the transwell insert were stained with DAPI. Each
membrane was scanned by fluorescence microscopy (EVOS FL Auto;
Thermo Fisher Scientific) and all the cells were automatically counted
using ImageJ software. Samples were analyzed in triplicate and per-
centage of cells relative to control is shown in the graphs. P values were
calculated by Student t test.
Cancer stem cells and colony-forming assays
A total of 5  102 cells were seeded in 6 wells plates and grown for
15 days. To maintain good growth conditions, the medium was
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changed every 48 hours. Cells were stained for 30 minutes with 0.1%
crystal violet dissolved in 10% of formaldehyde. Cells were washed
3 times with water and colonies were counted by automatic micros-
copy (EVOS FL Auto; Thermo Fisher Scientific). Differences in cancer
stem cells were measured as described previously (24).
Nude mouse orthotopic xenograft models
Five-weeks-old female athymic nude mice (Crl:CD1-Foxn1nu,
CDNSSFE05S) were purchased from Charles River. Guidelines of the
University of Verona Animal Ethic Committee were followed to house
animals in specific pathogen-free conditions and treat them. Subcon-
fluent cultures of pancreatic cancer cells were collected using 0.05%
trypsin-EDTA (GIBCO; ref. 25300-054). that was inhibited with 10%
FBS in DMEM. Tumor cells were resuspended in a solution of 1:1
Matrigel:PBS at 1.0  104 cells/mL concentration (Matrigel Matrix
Growth Factor; 356230; BD Biosciences). Orthotopic injection of
pancreatic cancer cells was performed as previously described in
ref. 25. We did not observe anesthesia-related deaths.
Antitumor activity of LY2090314 plus nab-paclitaxel in vivo in
AsPc1 pancreatic tumor orthotopic xenografts
AsPC1 orthotopic tumor-bearing mice were randomly assigned
(n ¼ 11 per group) to receive the following on a weekly schedule: (i)
vehicle (5% Tween-80 in saline) intraperitoneally (days 1–3–5); (ii)
LY2090314 (2.5mg/kg i.p., days 1–3); (iii) nab-paclitaxel (3mg/kg i.p.,
day 5); and their combinations: (4) nab-paclitaxel (3 mg/kg i.p., day 5)
plus LY2090314 (2.5mg/kg i.p., days 1–3). Treatments were continued
until progression.
Weight and tumor growth were measured weekly. When a prom-
inent mass was present in the mouse abdomen (tumor volume2,000
mm3), mice were euthanized by cervical dislocation, and that was
considered the day of death for survival evaluation. The median
survival duration was reached when at least half of the mice in each
treatment group were sacrificed.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue sections were subjected to
immunostaining using the streptavidin–peroxidase technique, with
diaminobenzidine (Immpact DAB, SK-4105; Vector Lab) as a chro-
mogen, as previously described in ref. 26. Either citrate pH 6.0
(ab93678; Abcam) or Tris-EDTA pH 9.0 (ab93684; Abcam) were
used as antigen retrieval buffers. Abcam primary rabbit monoclonal
antibodies to Ki67 (ab92742, 1:4,000), YAP (ab205270, 1:2,000), TAZ
(ab110239, 1:1,000), CTGF (ab6992, 1:600), AXL (ab72069, 1:100),
MMP7 (ab207299, 1:4,000), and CXCR4 (ab124824, 1:500) were used
at 4C overnight to stain sections. Incubation with ImmPRESS HRP
Anti-Rabbit IgG Peroxidase Polymer Detection Kit (MP-7401-50;
Vector Lab, Burlingame) was performed for 30 minutes; counter-
staining was performed with Vector Hematoxylin QS (H-3404; Vector
Lab) and slides were mounted using VectaMount Permanent Mount-
ing Medium (H-5000; Vector Lab).
Results
TAK1 prevents YAP/TAZ proteasomal degradation
To identify novel downstream signaling of TAK1 that could drive
the aggressiveness of pancreatic cancer, we analyzed differential gene
expression (GEO accession number GSE137265, https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc¼GSE137265) in AsPC1, Panc1,
and MDA-Panc28 pancreatic cancer cell lines transduced with lenti-
virus expressing TAK1-specific shRNA (shTAK1) or scramble
sequence as control (Fig. 1A) by using the IPA software. We found
a significant and consistent association of the genes modulated by
TAK1 silencing with the HIPPO, Wnt/b-catenin, and protein ubiqui-
tination pathways (Fig. 1B). To deepen our insight into the regulation
of the HIPPO pathway, we investigated whether YAP/TAZ expression
was affected by TAK1 silencing. We measured a downregulation of
YAP/TAZ proteins in stable shTAK1 cells as compared with their
respective controls, as well as an upregulation of b-catenin (Fig. 1C),
whichwas sustained by increasedGSK3a andGSK3bphosphorylation
in shTAK1 cell lines as compared with their controls (Supplementary
Fig. S1B). Consistently, we measured a significant (P < 0.01) down-
regulation of the YAP/TAZ regulated genesDKK1, CTGF, andAXL in
shTAK1 cells as comparedwith their respective controls (Fig. 1D). The
same downregulation of YAP/TAZ was demonstrated in cells tran-
siently transfected with siRNA sequences targeting TAK1 (Supple-
mentary Fig. S1C), which corroborated our findings and ruled out the
possibility that this could be due to shTAK1 off-target and/or long-
term adaptive effects. However, when we measured YAP/TAZmRNA
levels, we did not observe a consistent significant downregulation of
these genes in stable shTAK1 cells. A significant upregulation of YAP/
TAZ mRNA levels was measured in MDA-Panc28 cells silenced for
TAK1 expression as compared to their respective controls, which we
interpreted as a compensatory effect (Fig. 1E).
To test whether the modulation of YAP/TAZ by silencing of TAK1
could be related to TAK1 kinase activity, we treatedAsPC1, Panc1, and
MDA-Panc28 pancreatic cancer cell lines with the TAK1 kinase
inhibitors (5Z)-7-oxozeaenol. Effective inhibition of TAK1 kinase
activity was confirmed by suppression of IKK phosphorylation and
decrease in BIRC3 levels (Supplementary Fig. S2A). However, the
inhibition of TAK1 kinase activity did not decrease YAP/TAZ protein
levels in the 3 pancreatic cancer cell lines under investigation (Fig. 2A).
Conversely, when we transduced stable shTAK1 cells with a murine
K63W TAK1 kinase dead expressing vector, which could not be
targeted by human-specific shRNA sequences, we measured a signif-
icant rescue of the downregulation of YAP/TAZ proteins at levels
similar to those obtained by transducing themwith a wild-typemurine
TAK1 sequence. Moreover, this rescue contributed to rule out poten-
tial shTAK1 off-target effects (Fig. 2B). Altogether, these results
demonstrate that the expression of TAK1, rather than its kinase
activity, could affect YAP/TAZ stability.
In this regard, we investigated whether proteasomal degradation
could be involved inTAK1-mediatedmodulation of YAP/TAZprotein
stability. Treatment with proteasome inhibitor bortezomib increased
YAP/TAZ protein levels in all these cell lines. Interestingly, although
we observed only a modest increase in YAP/TAZ protein levels in
control cell lines, YAP/TAZwere strongly upregulated in shTAK1 cells
upon proteasomal inhibition with both bortezomib (Fig. 2C) and
MG-132 (Supplementary Fig. S2B). We investigated, thus, whether
silencing of TAK1 could modulate the expression of either K48 or K63
ubiquitin ligases. We measured lower protein levels of TRAF6 and
higher protein levels of ITCH in shTAK1 cells than in their respective
controls (Fig. 2D), as well as a decrease in total K63 ubiquitinated
proteins in shTAK1 cells than in their respective controls (Supple-
mentary Fig. S3A). Hence, we performed specific K63-linked and
K48-linked precipitations and we observed a decrease of K63-linked
and an increase in K48-linked ubiquitinated YAP/TAZ in shTAK1
cells as compared with their respective control (Fig. 2E). Accordingly,
YAP/TAZ immunoprecipitation followed by specific anti-K48
and anti-K63 ubiquitin immunoblot showed an increase in K48-
ubiquitinated and a decrease in K63-ubiquitinated YAP/TAZ in cells
silenced for TAK1 (Fig. 2F). To corroborate our data, we performed
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co-immunoprecipitations in AsPC1, Panc1, and MDA-Panc28 cells
andwe demonstrated the existence of a protein complex betweenYAP/
TAZ andTRAF6 (Supplementary Fig. S3B).Notably, we demonstrated
that the presence of TAK1was necessary for the formation of the YAP/
TAZ–TRAF6 complex (Fig. 2G).
Altogether, these data demonstrate that, independently by its kinase
activity, TAK1 protein levels can regulate YAP/TAZ protein stability
by fostering their K63-ubiquitination versus K48-ubiquitination
through the binding with TRAF6, thus preventing their proteasomal
degradation.
Modulating TAK1 levels through GSK3 inhibition reduces YAP/
TAZ protein levels and activities
To translate our findings into a therapeutic approach relevant for
patients presenting with pancreatic cancer, we took advantage of the
observation by Bang and colleagues (15) that GSK3 inhibition could
reduce TAK1 stability. Thus, we hypothesized that GSK3 inhibition
could be used to achieve a TAK1-mediated downregulation of
YAP/TAZ proteins.
To obtain a pharmacologic modulation of TAK1 expression, we
used 2 potent and highly selective inhibitors of GSK3a/b, LY2090314
and CHIR-99021, and the unselective GSK3 inhibitor LiCl, which acts
in an uncompetitive manner by displacing a divalent cation required
for GSK3 catalytic activity (27). This resulted in a substantial decrease
of YAP/TAZ and TAK1 protein levels in all the 3 pancreatic cancer cell
lines (Fig. 3A; Supplementary Fig. S4A). Treatment with the protea-
some inhibitor Bortezomib partially restored TAK1 and YAP/TAZ
protein levels (Fig. 3A). Similar to the TAK1 silencing, modulation of
TAK1 expression induced by GSK3 inhibition resulted in a significant
downregulation of YAP/TAZ regulated genes CTGF,AXL, and CYR61
in all the 3 pancreatic cancer cell lines (P < 0.05; Fig. 3B; Supple-
mentary Fig. S4B). As obtained by silencing TAK1 expression, treat-
ment with LY2090314 increased levels of GSK3 target b catenin
(Supplementary Fig. S4C). Similar effects were confirmed in FLO-1
andKYAE-1 esophageal cancer cell lines (Supplementary Fig. S5A and
S5B).
YAP/TAZ are known as important mediators of cell proliferation,
migration, anchorage-independent growth, and stemness (8); thus, we
evaluated whether modulation of TAK1 expression induced by GSK3
inhibitionwould impair these processes. Indeed, we demonstrated that
the selective GSK3 inhibitor LY2090314 significantly reduced cell
proliferation in control pancreatic cancer cell lines in the same extent
than did TAK1 silencing, while it was ineffective on TAK1 silenced
counterpart (Fig. 3C). Moreover, the inhibition of GSK3 significantly
reduced clonogenic potential (AsPC1, P < 0.001; Panc1, P < 0.001;
MDA-Panc28, P < 0.01; Fig. 3D), and consistently and significantly
impaired the migration ability of AsPC1, Panc1, and MDA-Panc28
cells (P < 0.05; Fig. 3E). Conversely, LY2090314 was completely
Figure 1.
Identification of TAK1-regulated pathways. A, Immunoblot analysis of the indicated cellular extracts. Numbers indicate the normalized ratio of TAK1 over nucleonin
signals obtained by densitometric analysis. B, Representation of selected TAK1-regulated pathways. Histograms show the significance values for the canonical
pathways as calculated by Fisher exact test right-tailed. Blue bars indicate predicted pathway inhibition (z-score) in shTAK1 cells as compared with their respective
controls. C, Immunoblot analysis of the indicated cellular extracts. Numbers indicate the normalized ratio of the indicated proteins over g-tubulin signals obtained by
densitometric analysis. D and E,Microarray data validation by qRT-PCR. Histograms show fold change in RNA expression between the gene of interest and b-actin.
Error bars indicate SD. NS, nonsignificant;  , P < 0.05;  , P < 0.01;  , P < 0.001.
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Figure 2.
TAK1modulates YAPandTAZubiquitination.A, Immunoblot analysis of cells treated for 48 hourswith theTAK1 kinase inhibitor (5Z)-7-oxozeaenol. Numbers indicate
the normalized ratio of YAP/TAZ over GAPDH signals obtained by densitometric analysis. B, Immunoblot analysis of cells transducedwith either K63W kinase-dead
orwild-type TAK1. Numbers indicate thenormalized ratio of YAP/TAZoverH3 signals obtainedbydensitometric analysis.C, Immunoblot analysis of cells treatedwith
the proteasome inhibitor bortezomib. Numbers indicate the normalized ratio of YAP/TAZ over GAPDH signals obtained by densitometric analysis. D, ITCH and
TRAF6protein levels in the indicated cellular extracts. Numbers indicate the normalized ratio of the indicated proteins overGAPDH signals obtainedby densitometric
analysis. E, Assessment of YAP/TAZ ubiquitination by K63 and K48 specific pull-down in the indicated cell lines. F, Immunoblot analysis of immunoprecipitated
YAP/TAZ using anti-K48– and anti-K63–specific antibodies in the indicated cell lines. Numbers indicate densitometric analysis. G, Immunoblot analysis of YAP/TAZ
immunoprecipitated complexes using the indicated antibodies. Asterisks indicate IgG heavy chains.
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Figure 3.
Pharmacologic inhibition of TAK1 by targetingGSK3 impairs YAP andTAZ levels andoncogenic activities.A, Immunoblot analyses ofAsPC1, Panc1 eMDA-Panc28 cell
lines treated with the GSK3 inhibitors LY2090314 or CHIR-99021 for 72 hours. Cell extracts were subjected to immunoblot with the indicated antibodies. Numbers
indicate the normalized ratio of the indicated proteins over GAPDH signals obtained by densitometric analysis. B,mRNA expression levels of the indicated YAP/TAZ
target genes overb-actin fromcells treated as inA. Error bars indicate SD.  ,P<0.05;  ,P<0.01.C,Growth curves of ctrl and shTAK1AsPC1 andPanc1 cell lines treated
with LY2090314 3 mmol/L. Means and SD of measurements performed in quadruplicate are shown. D, Colony formation assays of AsPC1, Panc1, and MDA-Panc28
treatedwith LiCl 20mmol/L, LY2090314 3mmol/L, or CHIR-99021 3mmol/L for 72 hours, and allowed to form colonies. A representative imageof colonies is shownon
the left. Histograms show colony number. Error bars indicate SD.  , P < 0.01; , P < 0.001. E,AsPC1, Panc1, andMDA-Panc28 cells were seeded and either treated or
not with LiCl 20 mmol/L, LY2090314 3 mmol/L, or CHIR-99021 3 mmol/L for 72 hours. Cells were then counted and seeded into the upper chamber of a transwell.
Sample images of migrated cells are shown. Histograms show the percentage of migrated cells. Error bars indicate SD.  , P < 0.05;  , P < 0.01.
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Figure 4.
Targeting GSK3 reduces cancer stem
cells features and chemoresistance of
pancreatic cancer cell lines. A, AsPC1
(left histogram), Panc1, and MDA-
Panc28 (right histograms) cell lines
were pulsed for 72 hours with the indi-
cated GSK3 inhibitors. 5  103 cells
were then seeded into ultra-low
attachment 6-well plates and cultured
in spheroids-forming medium for
52 days. Histograms show the per-
centage of CD133þ, CXCR4þ, CD24þ,
and CD44þ CSCs for Panc1 and
MDA-Panc28–derived spheroids and
CD133þ, CXCR4þ, CD24þ, CD44þ, and
EpCAMþ CSCs for AsPC1, as measured
by flow cytometry. Error bars indicate
SD.  , P < 0.05;  , P < 0.01; , P <
0.001. B, AsPC1, Panc1, and MDA-
Panc28 cells were either treated or not
with LY2090314 3 mmol/L or CHIR-
99021 3 mmol/L for 72 hours. 20 
103 cells were then seeded into ultra-
low attachment 96 wells plates in trip-
licate for 15 days to allow for spheroid
formation. Pictures show Z-stack
microphotographs of representative
wells. Histograms show the average
area of spheroids formed in each well.
Error bars indicate SD.  , P < 0.05;
 , P < 0.01;  , P < 0.001. C, AsPC1,
PANC1, and MDA-Panc28 cells were
pretreated with LY2090314 3 mmol/L
or dimethyl sulfoxide (DMSO) as con-
trol for 72 hours, and subsequently
treatedwith equitoxic increasing doses
of nab-paclitaxel and washed-out after
24 hours. Sulforhodamine B (SRB)
assay was used to obtain relative esti-
mates of viable cell number. Means and
95% confidence intervals are shown.
Curves were fitted by nonlinear regres-
sion analysis. Combination index (CI)
plot representing a quantitative mea-
sure of the degree of drug interaction
for a given end point of the effect
measurement is shown. D, Data were
analyzed for Bliss independence. Dose
matrix and synergy score are shown for
each cell line.
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ineffective in shTAK1 pancreatic cancer cell lines (Supplementary
Fig. S6A and S6B).
GSK3 inhibition impaired stemness as measured by a significant
reduction in both the percentage of CD133þ, CXCR4þ, CD24þ, and
CD44þ cancer stem cells (P < 0.05; Fig. 4A), and a decrease in the area
of spheroids growing in low-anchorage conditions (P < 0.05; Fig. 4B)
in all 3 pancreatic cancer cell lines, with the exception of CHIR-99021-
treated MDA-Panc28.
Altogether, these data demonstrate that GSK3 inhibition impairs
in vitro the aggressiveness of pancreatic cancer cells by targeting the
more relevant oncogenic functions sustained by YAP and TAZ.
GSK3 inhibitor LY2090314 modulates pancreatic cancer
chemoresistance by targeting the TAK1–YAP/TAZ axis
To test our hypothesis that the pharmacologic inhibition of GSK3
could be used tomodulate the chemoresistance of pancreatic cancer by
impairing YAP/TAZ prosurvival activities, including suppression of
apoptosis as previously published in ref. 28, we initially demonstrated
that the addition of LY2090314 resulted in an increase of Annexin Vþ
cells (Supplementary Fig. S7A) and PARP-1 cleavage (Supplementary
Fig. S7B). AsPC1, Panc1, and MDA-Panc28 pancreatic cancer cells
were, then, treated with increasing doses of classic chemotherapeutic
agents nab-paclitaxel, gemcitabine, oxaliplatin, or the activemetabolite
of irinotecan SN-38 in combination with LY2090314, or DMSO as
control. We demonstrated a highly synergistic effect between
LY2090314 and these chemotherapeutic agents against the 3 different
pancreatic cancer cell lines (Fig. 4C and D; Table 1; Supplementary
Fig. S8A–S8C). Combination treatment of LY2090314 plus nab-
paclitaxel resulted in a significant increase in PARP-1 cleavage
(Fig. S7C). Contrariwise to the effect observed in pancreatic cancer
cells, we measured a significant protective effect of LY2090314 on the
cytotoxic activity of nab-paclitaxel inHPDEnormal human pancreatic
duct epithelial cells (Supplementary Fig. S7D).
To demonstrate that LY2090314 could cooperate with clinically
relevant doses of nab-paclitaxel into an effective therapeutic approach
to inhibit the growth of pancreatic cancer in vivo, we used an
orthotopic xenograft nude mouse model. Forty mice were orthotopi-
cally injectedwithAsPC1humanpancreatic cancer cells and randomly
assigned to 4 treatment groups (n ¼ 10 per group). At the median
survival duration of mice in the control group (day 62), LY2090314
and nab-paclitaxel as single agents were completely inactive. However,
a statistically significant reduction in tumor volume was measured in
the mice treated with their combination if compared with untreated
controls (P < 0.05; Fig. 5A). Accordingly, we measure a statistically
significantly prolonged median survival duration only in mice treated
with the LY2090314 plus nab-paclitaxel combination [Fig. 5B, median
survival (days): control ¼ 62; nab-paclitaxel ¼ 64; LY2090314 ¼ 62;
LY2090314 plus nab-paclitaxel¼ 105,P< 0.05]. All regimenswerewell
tolerated. We did not observe weight loss or other signs of toxicity
(Supplementary Fig. S8D).
To confirm that the effects of LY2090314 treatment in vivo could be
related to themodulation of the TAK1–YAP/TAZ axis, we assessed the
expression of YAP/TAZ target genes in tumor specimens excised from
mice belonging to the control and LY2090314 groups. As expected, we
measured a relevant increase of the inhibitory Ser-21 phosphorylation
of GSK3a in mice treated with LY2090314 (Fig. 5C). Ser-9 phos-
phorylation of GSK3b was also induced, although to a lesser extent.
Consistently with the results in vitro, GSK3 inhibition led to a
measurable decrease in TAK1 and YAP/TAZ protein expression and,
in turn, to a reduction of the number of Ki67þ cells, and to a substantial
decrease of the expression of the YAP/TAZ regulated proteins AXL,
CTGF, MMP7, and a-SMA (Fig. 5C).
Altogether, these data demonstrated that the downregulation of the
expression of TAK1 obtained by using LY2090314 is a valid approach
to reduce YAP/TAZ protein levels in vitro and in vivo and, in turn, to
modulate the intrinsic chemoresistance of pancreatic cancer.
Discussion
In this study, we aimed to identify novel intracellular signaling
pathways regulated by TAK1. To our knowledge, this is the first study
to demonstrate that TAK1 regulates YAP and TAZ activity by inhibit-
ing their K48-linked ubiquitination and proteasomal degradation in a
kinase independent manner. In addition, we demonstrated that the
downregulation of the expression of TAK1 through the inhibition of
GSK3 is able to largely reduce YAP/TAZprotein levels and, in turn, the
transcription of the most relevant YAP/TAZ regulated genes both
in vitro and in vivo. In particular, the GSK3 inhibitor LY2090314
proved significantly and consistently effective in decreasing viability,
clonogenicity and CSC phenotype in 3 different models of pancreatic
cancer cell lines. Most importantly, treatment with LY2090314 sen-
sitized pancreatic cancer cells to the clinically relevant chemothera-
peutic agents nab-paclitaxel, gemcitabine, oxaliplatin, and SN38
in vitro, and it potentiated the effects of nab-paclitaxel in inhibiting
the growth of an in vivo orthotopic model of pancreatic cancer.
In recent years, several evidences suggested a putative integration of
TAK1 and YAP/TAZ, especially in orchestrating canonical and non-
canonical WNT signaling. YAP and TAZ have been demonstrated as
integral components of the b-catenin destruction complex, which
serves as their functional sink. Activation of canonical WNT signaling
causes rapid release of YAP/TAZ, leading to the activation of their
transcriptional program. Moreover, the presence of YAP/TAZ in the
destruction complex is necessary for the recruitment of bTrCP and
b-catenin degradation (29). Conversely, in a noncanonical WNT
pathway, Wnt5a induces a G-protein–mediated inhibition of LATS
kinase activity towards YAP/TAZ. In turn, the stable YAP/TAZ/TEAD
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transcription complex drives the transcription of secreted factors such
as DKK1, which inhibit canonical WNT pathway (30). In this regard,
TAK1 has been shown to mediate also noncanonical WNT signaling.
TAB1-dependent autophosphorylation and activation of TAK1 were
induced by Wnt1 stimulation, thus activating a Nemo-like kinase
(NLK)–MAPK cascade, and resulting in a TCF/LEF-dependent desta-
bilizationof theb-catenin/TCFcomplex interactionwithDNA(31,32).
The noncanonical Wnt5a/Ca2þ pathway activates TAK1–NLK–
MAPK cascade as well, resulting in inhibition of canonical b-catenin
signaling. However, the Wnt5a-mediated b-catenin inhibition was
only minimally affected by overexpression of a kinase-inactive mutant
of TAK1(K63W) (33). In a different study, expression of Wnt5A did
not induce TAK1 kinase activity or TCF phosphorylation (31). More
recently, noncanonical Wnt2 pathway was shown to activate TAK1,
which triggered metastasis-associated survival signals in circulating
tumor cells from pancreatic cancer patients (34). In this article, we
Figure 5.
Antitumor activity of LY2090314 plus nab-paclitaxel
in vivo in AsPC1 pancreatic tumor orthotopic xeno-
grafts (n ¼ 10 mice per group). A, Tumor volume was
quantified as the sumof all detectedphotonswithin the
region of the tumor per second. Error bars indicate SD.
 , P < 0.05, as determined by t test. B, Mice were
euthanized by cervical dislocation when presented
evidence of advanced bulky disease. Survival was
estimated since the day of orthotopic pancreatic can-
cer cells injection until the day of death. Differences
among survival duration of mice in each group were
determined by log-rank test.  , P < 0.05. C, Immuno-
histochemical analyses. FFPE sections from AsPC1
tumors treated as indicated were stained with the
indicated antibodies. 25 magnification images are
shown; image inserts show 10 magnification of the
same section. Histograms show percentage DAB
stained area for 3 independent IHC slides.  , P < 0.05.
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demonstrated that silencing TAK1 induces an inhibitory phosphor-
ylation of both GSK3a and GSK3b, which in turn stabilize b-catenin.
However, the mechanistic role of TAK1 in the activation of TAZ/YAP
remained still unexplored to date. In this study, we demonstrated that
TAK1 protein levels can regulate YAP/TAZ protein stability by
fostering their K63- vs. K48-ubiquitination thus preventing their
proteasomal degradation. This mechanism mediated by TAK1 is
independent by its kinase activity, and depends on the differential
modulation of the K63 E3 ubiquitin ligase TRAF6 and of the K48 E3
ubiquitin ligase ITCH.
Although the frequent aberrant activity of YAP/TAZ in a variety of
human cancers candidates these factors as ideal therapeutic targets, the
HIPPO cascade remains largely undruggable. Several other
approaches have been attempted to inhibit different signaling path-
ways controlling YAP/TAZ, including Rho/Rock and WNT, but
selectivity and toxicity of these agents represented serious limits for
their clinical development (35). More recently, the SREBP/mevalonate
pathway was also demonstrated to control YAP/TAZ activity, and the
inhibition of the rate-limiting enzyme of this pathway (HMG-CoA
reductase) by statins inhibited YAP/TAZ localization to the nucleus
and the activation of their transcriptional program (36). Although
some epidemiologic studies suggest a benefit from the addition of
statins to standard treatment regimens in patients with breast cancer
and prostate cancer, prospective clinical trials are still required to
further define the actual efficacy of this approach (37). In this
prospective, LY2090314 is a potent and selective ATP-competitive
inhibitor ofGSK3 already in clinical evaluation for cancer therapy. The
safety of LY2090314 as single-agent treatment or in combination with
pemetrexed and carboplatin was initially evaluated in a first-in-human
phase I dose-escalation study, in patients with advanced solid
tumors (38), and in an open-label phase II study in patients with
acute myeloid leukemia (39). Interestingly, an upregulation of b-cate-
nin was measured in peripheral blood mononuclear cells, indicating
that LY2090314 had an on-target effect on GSK3 inhibition.
This study, however, has some limitations. The pharmacologic
inhibition of GSK3 that we used to achieve a reduction in TAK1
stability could have potentially a direct effect on YAP/TAZ level,
regardless of the contribution of TAK1 in this pathway. In particular,
it has been recently demonstrated that inhibition of GSK3 as
key member of the destruction complex leads to the stabilization of
YAP/TAZ in mouse embryonic stem cells (40). Based on this model,
we would have expected an increase of YAP/TAZ levels under
treatment with LY2090314. On the contrary, wemeasured a significant
decrease of YAP/TAZ levels in pancreatic cancer cells treated with
GSK3 inhibitors. Moreover, we measured a significant increase in
b-catenin levels in cells silenced for TAK1 expression, indicating an
inactivation and not a stabilization of the destruction complex in these
models. These results suggest that in pancreatic cancer the role of
TAK1 activation in sustaining YAP/TAZ stability is probably more
relevant than their recruitment within the destruction complex.
In conclusion, our study demonstrates for the first time a crucial role
for TAK1 in controlling the activity of YAP/TAZ in pancreatic cancer.
Targeting TAK1 through the inhibition of GSK3 could be a promising
approach to modulate the oncogenic functions, ad in particular the
chemoresistance, sustained by YAP/TAZ in this disease. Our results
candidate LY2090314 as a novel agent that warrants further clinical
development in integrated therapeutic strategies (41) with chemo-
therapeutic agents such as nab-paclitaxel for the treatment of pan-
creatic cancer.
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